Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients / 中华医学杂志(英文版)

BACKGROUND@#This study aimed to determine the reasons for conversion and elucidate the safety and efficacy of transition to tenofovir alafenamide/emtricitabine/bictegravir sodium (TAF/FTC/BIC) in highly active antiretroviral therapy (HAART)-experienced HIV-infected patients in real-world settings.@*METHODS@#We conducted a retrospective cohort study. The treatment conversion rationales, safety, and effectiveness in 1684 HIV-infected patients with previous HAART experience who switched to TAF/FTC/BIC were evaluated at Beijing Ditan Hospital from September 2021 to Auguest 2022.@*RESULTS@#Regimen simplification (990/1684, 58.79%) was the most common reason for switching, followed by osteoporosis or osteopenia (375/1684, 22.27%), liver dysfunction (231/1684, 13.72%), decline in tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat (TAF/FTC/EVG/c) with food restriction (215/1684, 12.77%), virological failure (116/1684, 6.89%), and renal dysfunction (90/1684, 5.34%). In patients receiving non-nucleotide reverse transcriptase inhibitors (NNRTI)-containing regimens, lipid panel changes 1 year after switching indicated a difference of 3.27 ± 1.10 mmol/L vs . 3.40 ± 1.59 mmol/L in triglyceride ( P  = 0.014), 4.82 ± 0.74 mmol/L vs . 4.88 ± 0.72 mmol/L in total cholesterol ( P  = 0.038), 3.09 ± 0.70 mmol/L vs . 3.18 ± 0.66 mmol/L in low-density lipoprotein ( P  <0.001), and 0.99 ± 0.11 mmol/L vs . 0.95 ± 0.10 mmol/L in high-density lipoprotein ( P  <0.001). Conversely, among patients receiving booster-containing regimens, including TAF/FTC/EVG/c and lopinavir/ritonavir (LPV/r), lipid panel changes presented decreased trends. We also observed an improved trend in viral load suppression, and alanine transaminase (ALT), aspartate transaminase (AST), estimated glomerular filtration rate (eGFR), and serum creatinine levels after the transition ( P  <0.001).@*CONCLUSION@#The transition to TAF/FTC/BIC demonstrated good treatment potency. Furthermore, this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios, providing clinical evidence supporting the stable conversion to TAF/FTC/BIC for HAART-experienced patients.

Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1 / 中华医学杂志(英文版)

BACKGROUND@#Dual regimen dolutegravir (DTG) plus lamivudine (3TC) has demonstrated non-inferior efficacy compared to DTG-based three-drug regimens (3DRs), yet directly comparative data regarding the efficacy and safety of DTG + 3TC and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for therapy-naïve people with human immunodeficiency virus (HIV)-1 (PWH) are still limited. We aimed to assess the antiviral potency and safety profiles of DTG + 3TC vs. B/F/TAF based on antiretroviral therapy (ART)-naïve PWH in China.@*METHODS@#This retrospective multicenter study enrolled PWH initiating ART with DTG + 3TC or B/F/TAF from 2020 to 2022 in Guangdong and Guangxi. We analyzed response rates based on target not detected (TND) status using intention-to-treat (ITT) analysis. Subgroups were formed based on baseline viral load (VL) (<100,000 vs . ≥100,000 copies/mL) and CD4 + cell count (<200 vs . ≥200 cell/µL). Median time to TND VL was assessed by Kaplan-Meier method. We also measured changes from baseline in CD4 + cell counts, CD4/CD8 ratio, lipid parameters, weight, creatinine (Cr), estimated glomerular filtration rate (eGFR), and drug-related adverse effects (DRAEs).@*RESULTS@#We enrolled 280 participants, including 137 (48.9%) on DTG + 3TC and 143 (51.1%) on B/F/TAF. At week 48, 96.4% (132/137) on DTG+3TC and 100% (143/143) on B/F/TAF achieved TND ( P = 0.064). At week 12, TND responses were higher with B/F/TAF (78.3% [112/143]) than DTG+3TC (30.7% [42/137]) ( P <0.001). This trend held across subgroups. B/F/TAF achieved TND faster (12 weeks) than DTG+3TC (24 weeks) ( P <0.001). No differences were seen in CD4 + cell count and CD4/CD8 ratio, except in the high-VL subgroup, where B/F/TAF showed better recovery. DRAEs were significantly lower with B/F/TAF (4.9% [7/143]) than with DTG + 3TC (13.1% [18/137]) ( P = 0.016). Lipid parameters, body weight, and Cr increased in both groups over 48 weeks, with DTG+3TC showing a more favorable effect on triglycerides, high-density lipoprotein (HDL) cholesterol, and weight gain.@*CONCLUSIONS@#In this real-life study, B/F/TAF led to a faster viral decline and fewer DRAEs compared to DTG+3TC. No significant difference was observed in the TND rate at week 48, regardless of baseline VL and CD4 + cell count. CD4 + recovery was superior for B/F/TAF in participants with high VL. The DTG + 3TC regimen had less impact on metabolic changes than B/F/TAF.

Estudio de alteraciones neurocognitivas en pacientes infectados por el virus de la inmunodeficiencia humana / Study of neurocognitive alterations in patients infected by the human immunodeficiency virus

El virus de inmunodeficiencia humana, conocido por su impacto en el sistema inmunológico, ocasionamanifestacionesneurológicas progresivas con afectación cognitiva, perturbando funciones de atención, memoria, lenguaje, ejecución y procesamiento de la información, lo cual interfiere de forma negativa en la vida social, laboral y familiar del paciente. Objetivos: Evaluar las alteraciones de diferentes funciones neurocognitivas de los pacientes con infección por el virusde inmunodeficienciahumana, en una institución prestadora de servicios de salud de la cuidad de Ibagué - Colombia. Método: Se utilizó la Evaluación Cognitiva Montreal (MoCA), la cual fue diseñada como un instrumento ágil para determinar alteraciones cognitivas leves. La población objeto de estudio la constituyeron 44 pacientes portadores de virus de inmunodeficiencia humana, seleccionados dentro de un marco de muestreo no-probabilístico con muestra intencional o de conveniencia, entre los 14 y 75 años de edad. Resultados: Mayor deterioro neurocognitivo en los pacientes diagnosticados con virus de inmunodeficiencia humana de mayor edad; datos epidemiológicos indican que la edad más avanzada se asocia a una mayor prevalencia de desorden neurocognitivo asociado al virus de inmunodeficiencia humana. Conclusiones: El estudio de los mecanismos del deterioro neurocognitivo en pacientes con virus de inmunodeficiencia humana se hace cada vez más relevante, porque cada día aumenta su esperanza de vida, pero a su vez genera complicaciones con mayor predominio de la comorbilidad médica, psiquiátrica y neurológica(AU)

Introduction: The Human Immunodeficiency Virus, known for its impact on the immune system, causes progressive neurologic manifestations with cognitive impairment, disrupting attention functions, memory, language, execution and processing of information. The latter negatively interferes in social, work and family life of the patient. Objectives: To evaluate alterations in varied neurocognitive functions on patients with Human Immunodeficiency Virusinfection, at a health institution in Ibague, Colombia. Method: The Montreal Cognitive Assessment (MoCA) was used. It was designed as a tool to determine mild cognitive alterations. The study population was made up of 44 carriers of Human Immunodeficiency Virus who were selected within a framework of non-probabilistic sampling and with purposive sample or convenience, between 14 and 75 years old. Results: Greater neurocognitive impairment in patients diagnosed with Human Immunodeficiency Virus in legal age; someepidemiological data indicate that the older age is associated with a higher prevalence of neurocognitive disorder associated with Human Immunodeficiency Virus. Conclusions: The study of the neurocognitive impairment mechanisms in patients with Human Immunodeficiency Virus becomes increasingly more relevant, as their life expectancy increases daily. On the other hand, it causes complications with greater prevalence of medical psychiatric and neurological comorbidity(AU)